Hospital
Banner Estrella Medical Center
Banner Estrella Medical Center was paid $108.10M by Medicaid between Jan 2018 and Dec 2024, across 412 billing codes. Its largest line is 99285, emergency room visit (most serious) — 23% of everything it billed.
33Billing provider infoBANNER ESTRELLA MEDICAL CENTER
PHOENIX, AZ 85037
PHOENIX, AZ 85037
33aNPI1275566200assigned 07/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$108.10M
24GClaims3,027,891
24DCodes billed412
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#3 of 78
Median peer was paid$12.21M
This provider vs. median8.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 452,155 | $17.41M | |
| 2019 | 424,847 | $17.15M | |
| 2020 | 352,667 | $14.50M | |
| 2021 | 436,947 | $15.93M | |
| 2022 | 462,695 | $14.89M | |
| 2023 | 486,686 | $15.14M | |
| 2024incomplete | 411,894 | $13.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 23% | 79,578 | 71,391 | $25.25M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 96,355 | 89,106 | $20.37M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 13% | 24,299 | 22,815 | $13.98M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.7% | 57,198 | 54,061 | $10.47M |
| 47562 | 5.7% | 1,843 | 1,742 | $6.20M | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.8% | 11,350 | 10,540 | $4.10M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 22,607 | 20,893 | $2.07M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.8% | 2,033 | 1,886 | $1.97M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 17,950 | 17,193 | $1.94M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.8% | 7,372 | 6,902 | $1.91M |
| 70496 | 1.7% | 3,015 | 2,812 | $1.87M | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1.3% | 920 | 851 | $1.40M |
400 more codes
| 72125 | Computed tomography, cervical spine; without contrast material | 1.2% | 5,564 | $1.35M |
| 58661 | <1% | 338 | $1.06M | |
| G0378 | Hospital observation service, per hour | <1% | 47,461 | $1.02M |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 9,843 | $921K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,202 | $906K |
| 49083 | <1% | 3,985 | $768K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,914 | $735K |
| 74174 | <1% | 1,040 | $599K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 5,758 | $533K |
| 44970 | <1% | 124 | $479K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 6,003 | $400K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,304 | $399K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 4,369 | $394K |
| 70491 | <1% | 1,206 | $386K | |
| 93458 | <1% | 264 | $332K | |
| 93970 | <1% | 2,129 | $331K | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 1,065 | $312K |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 343 | $283K |
| C1776 | Joint device (implantable) | <1% | 179 | $262K |
| 72131 | <1% | 685 | $245K | |
| 72193 | <1% | 579 | $222K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 24,714 | $221K |
| 58558 | <1% | 148 | $212K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,315 | $207K |
| 70487 | <1% | 701 | $206K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 4,679 | $199K |
| 70486 | <1% | 2,605 | $197K | |
| 58571 | <1% | 28 | $170K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 6,994 | $160K |
| C1769 | Guide wire | <1% | 4,093 | $157K |
| 93971 | <1% | 4,826 | $151K | |
| 43235 | <1% | 349 | $132K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,800 | $130K |
| 50590 | <1% | 62 | $108K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 81,631 | $105K |
| 59025 | Fetal non-stress test | <1% | 3,252 | $101K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 148 | $98K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,996 | $98K |
| 88341 | <1% | 1,116 | $96K | |
| 80053 | Comprehensive metabolic panel | <1% | 141,167 | $90K |
| 58670 | <1% | 26 | $87K | |
| 71250 | <1% | 1,065 | $85K | |
| 77012 | <1% | 330 | $85K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 221 | $84K |
| 52332 | <1% | 46 | $78K | |
| 70498 | <1% | 3,037 | $69K | |
| 88307 | <1% | 1,762 | $66K | |
| J0716 | Injection, centruroides immune f(ab)2, up to 120 milligrams | <1% | 16 | $66K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 197 | $60K |
| 10060 | <1% | 1,215 | $57K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 9,419 | $48K |
| 76818 | <1% | 1,545 | $47K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 2,810 | $46K |
| 94060 | <1% | 156 | $41K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 75,173 | $38K |
| 52356 | <1% | 12 | $36K | |
| 93976 | <1% | 7,019 | $35K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 126 | $35K |
| 93798 | <1% | 675 | $33K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 30 | $31K |
| 71045 | Radiologic examination, chest; single view | <1% | 46,996 | $29K |
| 80320 | <1% | 11,504 | $28K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 10,190 | $28K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 25,440 | $27K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 522 | $26K |
| 93975 | <1% | 221 | $24K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 16,674 | $23K |
| 36561 | <1% | 13 | $20K | |
| 96376 | <1% | 28,395 | $18K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 64,862 | $18K |
| 0450 | Emergency room services | <1% | 363 | $15K |
| 76801 | <1% | 8,047 | $15K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 13,632 | $14K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 29,860 | $14K |
| 73700 | <1% | 71 | $13K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 158,332 | $13K |
| C1781 | Mesh (implantable) | <1% | 386 | $12K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,460 | $12K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 4,008 | $12K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 7,423 | $11K |
| 87631 | <1% | 3,567 | $11K | |
| J3490 | Unclassified drugs | <1% | 87,371 | $10K |
| 88185 | <1% | 19 | $10K | |
| 72146 | <1% | 41 | $8K | |
| 12001 | <1% | 2,049 | $8K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 15,573 | $8K |
| 84484 | <1% | 59,990 | $8K | |
| 72141 | <1% | 208 | $8K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 40,627 | $7K |
| 36430 | <1% | 1,636 | $7K | |
| 73701 | <1% | 13 | $7K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,777 | $7K |
| 73130 | <1% | 4,233 | $7K | |
| 73030 | <1% | 4,990 | $6K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,878 | $6K |
| 73562 | <1% | 6,085 | $6K | |
| 72100 | <1% | 2,848 | $5K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 862 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 62,189 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 34,412 | $5K |
| 83690 | <1% | 48,596 | $5K | |
| 73610 | <1% | 4,011 | $4K | |
| 82803 | <1% | 2,920 | $4K | |
| 81025 | <1% | 45,649 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 131 | $4K |
| 73630 | <1% | 4,433 | $4K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,440 | $4K |
| 72128 | <1% | 75 | $4K | |
| 76830 | Ultrasound, transvaginal | <1% | 4,340 | $4K |
| 82731 | <1% | 340 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 40,839 | $3K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $3K |
| 81001 | <1% | 61,925 | $3K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,726 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 44,555 | $3K |
| 80329 | <1% | 1,970 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,032 | $3K |
| 76770 | <1% | 438 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,691 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 11,178 | $3K |
| 82947 | <1% | 58,109 | $2K | |
| 73110 | <1% | 2,846 | $2K | |
| 12011 | <1% | 1,457 | $2K | |
| 83605 | <1% | 24,148 | $2K | |
| 88342 | <1% | 2,421 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,726 | $2K |
| 83735 | <1% | 28,070 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 35,445 | $2K |
| 84702 | <1% | 15,992 | $2K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 122 | $2K |
| 73080 | <1% | 1,873 | $2K | |
| 83880 | <1% | 11,413 | $2K | |
| 74018 | <1% | 2,639 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,955 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,624 | $2K |
| 87081 | <1% | 2,658 | $2K | |
| 87040 | <1% | 18,524 | $2K | |
| 82550 | <1% | 7,023 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 13,123 | $1K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 65 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 19,522 | $1K |
| 73590 | <1% | 2,249 | $1K | |
| 86850 | <1% | 10,665 | $1K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 139 | $1K |
| 73090 | <1% | 1,872 | $1K | |
| 76775 | <1% | 58 | $1K | |
| 73502 | <1% | 2,390 | $1K | |
| 87088 | <1% | 23,798 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 5,413 | $1K |
| 76870 | <1% | 1,101 | $1K | |
| 81003 | <1% | 24,875 | $988.33 | |
| 71101 | <1% | 1,028 | $971.70 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,851 | $955.36 |
| 82010 | <1% | 3,144 | $945.91 | |
| 73140 | <1% | 886 | $934.60 | |
| 87186 | <1% | 9,098 | $918.65 | |
| 85379 | <1% | 6,587 | $904.61 | |
| 86923 | <1% | 1,466 | $887.68 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 9,394 | $859.32 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 31,106 | $833.16 |
| 87075 | <1% | 2,646 | $824.78 | |
| 84703 | <1% | 9,993 | $808.48 | |
| 72040 | <1% | 794 | $804.38 | |
| 90715 | <1% | 4,547 | $780.73 | |
| 12002 | <1% | 1,169 | $779.30 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 9,529 | $749.13 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 861 | $741.80 |
| 97161 | <1% | 4,244 | $668.57 | |
| 86901 | <1% | 14,617 | $660.16 | |
| 73060 | <1% | 458 | $630.39 | |
| 85027 | <1% | 25,168 | $628.99 | |
| 87210 | <1% | 8,613 | $628.51 | |
| 84100 | <1% | 4,066 | $613.76 | |
| C1729 | Catheter, drainage | <1% | 1,963 | $600.82 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 101,823 | $590.75 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 17,236 | $588.71 |
| 96367 | <1% | 3,308 | $573.79 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 237 | $560.17 |
| 87077 | <1% | 10,985 | $538.95 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,763 | $528.79 |
| 94729 | <1% | 150 | $527.44 | |
| 85610 | <1% | 27,351 | $461.29 | |
| 84145 | <1% | 4,166 | $418.71 | |
| 93017 | <1% | 36 | $415.27 | |
| 84439 | <1% | 2,355 | $397.30 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,018 | $390.85 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 15 | $374.10 |
| 84156 | <1% | 3,563 | $361.25 | |
| 85730 | <1% | 13,121 | $355.08 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,996 | $345.61 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 3,044 | $344.66 |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,822 | $342.15 |
| A9270 | Non-covered item or service | <1% | 117,945 | $327.66 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 1,143 | $316.79 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,558 | $310.16 |
| J1815 | Injection, insulin, per 5 units | <1% | 16,801 | $308.13 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 14,564 | $286.90 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 1,902 | $281.97 |
| 85055 | <1% | 4,513 | $281.07 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,425 | $277.88 |
| 86900 | <1% | 11,709 | $271.37 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 28,487 | $262.75 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 6,878 | $257.44 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,136 | $235.02 |
| 93880 | <1% | 43 | $233.00 | |
| 73552 | <1% | 299 | $231.19 | |
| J2704 | Injection, propofol, 10 mg | <1% | 19,276 | $231.04 |
| 85018 | <1% | 4,583 | $230.10 | |
| 85014 | <1% | 2,934 | $216.04 | |
| 84112 | <1% | 1,888 | $209.54 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 10,508 | $204.30 |
| 97116 | <1% | 2,727 | $203.54 | |
| 29125 | <1% | 653 | $202.28 | |
| 72170 | <1% | 499 | $200.87 | |
| 94664 | <1% | 1,223 | $199.26 | |
| 86140 | <1% | 7,179 | $194.15 | |
| 80061 | Lipid panel | <1% | 3,610 | $190.88 |
| 88304 | <1% | 3,104 | $169.98 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 1,430 | $169.81 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,557 | $160.21 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 390 | $151.30 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 3,809 | $148.95 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 6,092 | $148.36 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,505 | $144.10 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 4,849 | $140.31 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,341 | $137.26 |
| 72072 | <1% | 337 | $129.03 | |
| 86920 | <1% | 270 | $126.55 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 6,424 | $117.34 |
| 82140 | <1% | 1,324 | $115.37 | |
| 87147 | <1% | 1,190 | $107.05 | |
| 96368 | <1% | 903 | $104.26 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,750 | $99.04 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 4,779 | $97.60 |
| 82330 | <1% | 913 | $96.58 | |
| 82565 | <1% | 6,057 | $93.87 | |
| 86635 | <1% | 1,045 | $92.44 | |
| 87070 | <1% | 4,891 | $92.24 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 6,874 | $80.52 |
| 94760 | <1% | 1,612 | $80.16 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,838 | $79.46 |
| 94660 | <1% | 42 | $72.68 | |
| 84466 | <1% | 996 | $72.62 | |
| 51702 | <1% | 281 | $72.35 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 4,603 | $72.26 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 15,834 | $70.59 |
| 82728 | <1% | 690 | $69.39 | |
| C9399 | Unclassified drugs or biologicals | <1% | 458 | $63.97 |
| 89051 | <1% | 3,501 | $63.74 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 3,065 | $60.28 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,761 | $58.86 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,688 | $58.63 |
| 87807 | <1% | 798 | $51.44 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 1,690 | $44.81 |
| 87205 | <1% | 5,207 | $42.45 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,863 | $40.59 |
| 83540 | <1% | 1,028 | $38.60 | |
| 84132 | <1% | 4,294 | $37.21 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 107 | $36.80 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 676 | $36.00 |
| 90686 | <1% | 707 | $33.69 | |
| 84550 | <1% | 3,113 | $28.70 | |
| 85652 | <1% | 2,765 | $27.71 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 3,397 | $26.86 |
| 80051 | <1% | 496 | $22.39 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 5,383 | $20.82 |
| 84520 | <1% | 2,848 | $19.63 | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 194 | $18.90 |
| 82570 | <1% | 777 | $18.01 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 245 | $17.84 |
| 76857 | <1% | 69 | $17.69 | |
| 84460 | <1% | 2,413 | $17.59 | |
| 85046 | <1% | 582 | $17.12 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,457 | $14.74 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,606 | $10.56 |
| 84450 | <1% | 2,163 | $10.37 | |
| 85384 | <1% | 820 | $8.95 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 1,999 | $8.91 |
| 84300 | <1% | 119 | $8.64 | |
| 82270 | <1% | 593 | $8.59 | |
| 86706 | <1% | 38 | $8.59 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 2,709 | $8.23 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 66 | $5.10 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 622 | $5.04 |
| 85007 | <1% | 96 | $4.88 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 418 | $3.87 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,827 | $3.28 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 326 | $2.75 |
| 36415 | Collection of venous blood by venipuncture | <1% | 34 | $2.70 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 1,105 | $2.43 |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,654 | $2.40 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 419 | $2.20 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 370 | $1.81 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,649 | $0.60 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 210 | $0.01 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 121 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 416 | $0.00 |
| 0042T | 0% | 408 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 763 | $0.00 |
| 85460 | 0% | 606 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 982 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 2,182 | $0.00 |
| 88112 | 0% | 199 | $0.00 | |
| 87899 | 0% | 50 | $0.00 | |
| 29515 | 0% | 294 | $0.00 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 1,785 | $0.00 |
| 99152 | 0% | 82 | $0.00 | |
| 87254 | 0% | 17 | $0.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 210 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 442 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 55 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 214 | $0.00 |
| 82042 | 0% | 15 | $0.00 | |
| 88302 | 0% | 244 | $0.00 | |
| 80074 | 0% | 40 | $0.00 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 0% | 146 | $0.00 |
| 80164 | 0% | 57 | $0.00 | |
| 92610 | 0% | 151 | $0.00 | |
| 73070 | 0% | 92 | $0.00 | |
| 62270 | 0% | 14 | $0.00 | |
| 36600 | 0% | 15 | $0.00 | |
| 84295 | 0% | 39 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 13 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 82 | $0.00 |
| 76376 | 0% | 97 | $0.00 | |
| 94726 | 0% | 139 | $0.00 | |
| 80076 | 0% | 12 | $0.00 | |
| 97163 | 0% | 12 | $0.00 | |
| 85049 | 0% | 42 | $0.00 | |
| 93041 | 0% | 206 | $0.00 | |
| 29505 | 0% | 14 | $0.00 | |
| 70360 | 0% | 25 | $0.00 | |
| 80202 | 0% | 12 | $0.00 | |
| 87324 | 0% | 84 | $0.00 | |
| C1788 | Port, indwelling (implantable) | 0% | 13 | $0.00 |
| 31500 | 0% | 34 | $0.00 | |
| 93356 | 0% | 13 | $0.00 | |
| 87102 | 0% | 46 | $0.00 | |
| 87045 | 0% | 29 | $0.00 | |
| 73100 | 0% | 43 | $0.00 | |
| C1874 | Stent, coated/covered, with delivery system | 0% | 16 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 15 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 12 | $0.00 |
| 88313 | 0% | 95 | $0.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 22 | $0.00 |
| 85347 | 0% | 15 | $0.00 | |
| J2590 | Injection, oxytocin, up to 10 units | 0% | 18 | $0.00 |
| J0612 | Injection, calcium gluconate, not otherwise specified, 10 mg | 0% | 14 | $0.00 |
| 97165 | 0% | 1,464 | $0.00 | |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 163 | $0.00 |
| 94762 | 0% | 590 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 630 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 739 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,698 | $0.00 |
| 74420 | 0% | 713 | $0.00 | |
| 97162 | 0% | 753 | $0.00 | |
| 73600 | 0% | 95 | $0.00 | |
| 82607 | 0% | 369 | $0.00 | |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 135 | $0.00 |
| 82945 | 0% | 226 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 385 | $0.00 |
| 99292 | 0% | 107 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 196 | $0.00 |
| G0379 | Direct admission of patient for hospital observation care | 0% | 66 | $0.00 |
| 87206 | 0% | 242 | $0.00 | |
| 73560 | 0% | 105 | $0.00 | |
| G0009 | Administration of pneumococcal vaccine | 0% | 28 | $0.00 |
| 87116 | 0% | 131 | $0.00 | |
| 87449 | 0% | 220 | $0.00 | |
| 84157 | 0% | 573 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 519 | $0.00 |
| 87184 | 0% | 83 | $0.00 | |
| 83615 | 0% | 128 | $0.00 | |
| 86308 | 0% | 68 | $0.00 | |
| 87340 | 0% | 105 | $0.00 | |
| 87046 | 0% | 29 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 45 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 20 | $0.00 |
| 90732 | 0% | 27 | $0.00 | |
| J3535 | Drug administered through a metered dose inhaler | 0% | 20 | $0.00 |
| 74022 | 0% | 14 | $0.00 | |
| 82746 | 0% | 65 | $0.00 | |
| 86592 | 0% | 43 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 17 | $0.00 |
| 97166 | 0% | 25 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 31 | $0.00 |
| 74021 | 0% | 46 | $0.00 | |
| 73120 | 0% | 37 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 326 | $0.00 |
| Q5105 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units | 0% | 22 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 34 | $0.00 |
| 73620 | 0% | 30 | $0.00 | |
| 88184 | 0% | 18 | $0.00 | |
| 86870 | 0% | 35 | $0.00 | |
| 29130 | 0% | 27 | $0.00 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 15 | $0.00 |
| 80177 | 0% | 13 | $0.00 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 12 | $0.00 |
| 94644 | 0% | 12 | $0.00 | |
| 84478 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialOPHAUG, COURTNEY (CEO)
Parent organizationBANNER HEALTH